These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22632372)

  • 1. Prevention of Graves' ophthalmopathy.
    Bartalena L
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):371-9. PubMed ID: 22632372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of thyroid associated-ophthalmopathy in children and adults: current views and management of preventable risk factors.
    Krassas GE; Perros P
    Pediatr Endocrinol Rev; 2007 Mar; 4(3):218-24. PubMed ID: 17551483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating the thyroid in the presence of Graves' ophthalmopathy.
    Hegedüs L; Bonnema SJ; Smith TJ; Brix TH
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):313-24. PubMed ID: 22632368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graves' ophthalmopathy and 131I therapy.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
    Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical update: treatment of hyperthyroidism in Graves' ophthalmopathy.
    Azzam I; Tordjman K
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():193-7. PubMed ID: 20467362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and prevention of Graves' ophthalmopathy.
    Wiersinga WM; Bartalena L
    Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tale of radioiodine and Graves' orbitopathy.
    Ponto KA; Zang S; Kahaly GJ
    Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
    Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
    Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.
    Träisk F; Tallstedt L; Abraham-Nordling M; Andersson T; Berg G; Calissendorff J; Hallengren B; Hedner P; Lantz M; Nyström E; Ponjavic V; Taube A; Törring O; Wallin G; Asman P; Lundell G;
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3700-7. PubMed ID: 19723755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.
    Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
    Bartalena L
    J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
    Batra R; Krishnasamy SK; Buch H; Sandramouli S
    Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Graves' ophthalmopathy.
    Wiersinga WM
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric aspects in Graves' orbitopathy.
    Gogakos AI; Boboridis K; Krassas GE
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():234-44. PubMed ID: 20467370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
    Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
    Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
    [No Abstract]   [Full Text] [Related]  

  • 17. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
    Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
    Krassas GE; Segni M; Wiersinga WM
    Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
    Marcocci C; Marinò M
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of radioiodine therapy on ocular changes and their relation to urine cotinine level in patients with Graves' Ophthalmopathy.
    Czarnywojtek A; Zgorzalewicz-Stachowiak M; Budny B; Wasko R; Florek E; Szczepanek E; Komar-Rychlicka K; Waligorska-Stachura J; Kurdybacha P; Miechowicz I; Ruchala M
    Neuro Endocrinol Lett; 2013; 34(3):241-8. PubMed ID: 23685424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.